Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Metformin and Autoimmunity: A "New Deal" of an Old Drug.

Ursini F, Russo E, Pellino G, D'Angelo S, Chiaravalloti A, De Sarro G, Manfredini R, De Giorgio R.

Front Immunol. 2018 Jun 4;9:1236. doi: 10.3389/fimmu.2018.01236. eCollection 2018. Review.

2.

Post-translational regulation of macrophage migration inhibitory factor: Basis for functional fine-tuning.

Schindler L, Dickerhof N, Hampton MB, Bernhagen J.

Redox Biol. 2018 May;15:135-142. doi: 10.1016/j.redox.2017.11.028. Epub 2017 Dec 6. Review.

3.

Evaluation of MIF -173 G/C Polymorphism in Turkish Patients with Ankylosing Spondylitis.

Gürel Ç, İnanır A, Nursal AF, Tekcan A, Rüstemoğlu A, Yigit S.

Balkan Med J. 2016 Nov;33(6):614-619. Epub 2016 Nov 1.

4.

Independent association of glucocorticoids with damage accrual in SLE.

Apostolopoulos D, Kandane-Rathnayake R, Raghunath S, Hoi A, Nikpour M, Morand EF.

Lupus Sci Med. 2016 Nov 22;3(1):e000157. eCollection 2016.

5.

Association of Macrophage Migration Inhibitory Factor Polymorphisms with Total Plasma IgE Levels in Patients with Atopic Dermatitis in Korea.

Kim JS, Choi J, Hahn HJ, Lee YB, Yu DS, Kim JW.

PLoS One. 2016 Sep 6;11(9):e0162477. doi: 10.1371/journal.pone.0162477. eCollection 2016.

6.

Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus.

Connelly KL, Kandane-Rathnayake R, Hoi A, Nikpour M, Morand EF.

Sci Rep. 2016 Jul 25;6:29909. doi: 10.1038/srep29909.

7.
8.

Macrophage migration inhibitory factor -173 G/C polymorphism is associated with an increased risk of pulmonary tuberculosis in Zahedan, Southeast Iran.

Hashemi M, Sharifi-Mood B, Rasouli A, Amininia S, Naderi M, Taheri M.

EXCLI J. 2015 Jan 21;14:117-22. doi: 10.17179/excli2014-636. eCollection 2015.

9.

MIF: Implications in the Pathoetiology of Systemic Lupus Erythematosus.

Lang T, Foote A, Lee JP, Morand EF, Harris J.

Front Immunol. 2015 Nov 11;6:577. doi: 10.3389/fimmu.2015.00577. eCollection 2015. Review.

10.

Macrophage migration inhibitory factor polymorphism is associated with susceptibility to inflammatory coronary heart disease.

Ji K, Wang X, Li J, Lu Q, Wang G, Xue Y, Zhang S, Qian L, Wu W, Zhu Y, Wang L, Liao L, Tang J.

Biomed Res Int. 2015;2015:315174. doi: 10.1155/2015/315174. Epub 2015 Mar 4.

11.

Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention.

Wigren M, Nilsson J, Kaplan MJ.

J Intern Med. 2015 Nov;278(5):494-506. doi: 10.1111/joim.12357. Review.

12.

Influence of molecular genetics in Vogt-Koyanagi-Harada disease.

Ng JY, Luk FO, Lai TY, Pang CP.

J Ophthalmic Inflamm Infect. 2014 Jul 22;4:20. doi: 10.1186/s12348-014-0020-1. eCollection 2014. Review.

13.

Dual effect of a polymorphism in the macrophage migration inhibitory factor gene is associated with new-onset Graves disease in a Taiwanese Chinese population.

Liu YH, Chen CC, Yang CM, Chen YJ, Tsai FJ.

PLoS One. 2014 Mar 25;9(3):e92849. doi: 10.1371/journal.pone.0092849. eCollection 2014.

14.

Macrophage migration inhibitory factor: association of -794 CATT5-8 and -173 G>C polymorphisms with TNF-α in systemic lupus erythematosus.

De la Cruz-Mosso U, Bucala R, Palafox-Sánchez CA, Parra-Rojas I, Padilla-Gutiérrez JR, Pereira-Suárez AL, Rangel-Villalobos H, Vázquez-Villamar M, Angel-Chávez LI, Muñoz-Valle JF.

Hum Immunol. 2014 May;75(5):433-9. doi: 10.1016/j.humimm.2014.02.014. Epub 2014 Feb 12.

15.

A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still's disease.

Wang FF, Huang XF, Shen N, Leng L, Bucala R, Chen SL, Lu LJ.

Arthritis Res Ther. 2013;15(3):R65.

16.

Virtual screening and optimization yield low-nanomolar inhibitors of the tautomerase activity of Plasmodium falciparum macrophage migration inhibitory factor.

Dahlgren MK, Garcia AB, Hare AA, Tirado-Rives J, Leng L, Bucala R, Jorgensen WL.

J Med Chem. 2012 Nov 26;55(22):10148-59. doi: 10.1021/jm301269s. Epub 2012 Oct 26.

17.

A novel allosteric inhibitor of macrophage migration inhibitory factor (MIF).

Bai F, Asojo OA, Cirillo P, Ciustea M, Ledizet M, Aristoff PA, Leng L, Koski RA, Powell TJ, Bucala R, Anthony KG.

J Biol Chem. 2012 Aug 31;287(36):30653-63. doi: 10.1074/jbc.M112.385583. Epub 2012 Jul 10.

18.

Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus.

Sreih A, Ezzeddine R, Leng L, LaChance A, Yu G, Mizue Y, Subrahmanyan L, Pons-Estel BA, Abelson AK, Gunnarsson I, Svenungsson E, Cavett J, Glenn S, Zhang L, Montgomery R, Perl A, Salmon J, Alarcón-Riquelme ME, Harley JB, Bucala R.

Arthritis Rheum. 2011 Dec;63(12):3942-51. doi: 10.1002/art.30624.

19.

Macrophage migration inhibitory factor: a multifunctional cytokine in rheumatic diseases.

Kasama T, Ohtsuka K, Sato M, Takahashi R, Wakabayashi K, Kobayashi K.

Arthritis. 2010;2010:106202. doi: 10.1155/2010/106202. Epub 2010 Dec 26.

20.

A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice.

Leng L, Chen L, Fan J, Greven D, Arjona A, Du X, Austin D, Kashgarian M, Yin Z, Huang XR, Lan HY, Lolis E, Nikolic-Paterson D, Bucala R.

J Immunol. 2011 Jan 1;186(1):527-38. doi: 10.4049/jimmunol.1001767. Epub 2010 Nov 24.

Supplemental Content

Support Center